Table 1.
Baseline demographics and clinical data
| No. of patients | 62 |
| Gender (M:F) | 16:46 |
| Age at time of surgery (years) | 52.6 ± 12.2 |
| Body weight (kg) | 52.9 (46–65) |
| Underlying renal diagnosis, no. of patients (%) | |
| Diabetic nephropathy | 9 (14.5) |
| Hypertensive nephropathy | 10 (16.1) |
| Polycystic kidney | 4 (6.5) |
| Glomerulonephritis | 20 (32.2) |
| Unknown | 19 (30.6) |
| RRT at time of surgery | |
| PD | 45 (72.6) |
| HD | 17 (27.4) |
| Duration of dialysis (years) | 5.9 ± 2.6 |
| Kt/V (weekly) | 2.31 ± 0.9 |
| Preoperative serum biochemistry | |
| iPTH–peak (pmol/L) | 170 (131–221) |
| iPTH–immediately before operation (pmol/L) | 156.5 (122–215) |
| ALP–peak (IU/L) | 309.5 (192–511) |
| ALP–immediately before operation (IU/L) | 261 (161–447) |
| Calciuma (mmol/L) | 2.57 ± 0.21 |
| Phosphate (mmol/L) | 2.28 ± 0.65 |
| Albumin (g/L) | 31 ± 5 |
| Haemoglobin (g/dL) | 9.9 ± 1.5 |
| Preoperative drug treatment | |
| Phosphate binders (n = 31) | |
| Calcium carbonate (n = 21) (mg/day) | 2904.8 ± 1921.1 |
| Aluminium hydroxide (n = 4) (mg/day) | 1400.0 ± 632.5 |
| Lanthanum (n = 3) (mg/day) | 1083.3 ± 381.9 |
| Sevelamer (n = 4) (mg/day) | 2100.0 ± 1194.4 |
| Active vitamin D (n = 23) | |
| Calcitriol (n = 3) (μg/week) | 1.00 ± 0.50 |
| Alfacalcidol (n = 12) (μg/week) | 1.17 ± 0.83 |
| Paricalcitol (n = 8) (μg/week) | 24.00 ± 14.30 |
| Cinacalcet (n = 14) (mg/day) | 35.7 ± 16.2 |
| Surgical procedure, no. of patients (%) | |
| 4 glands resected | 48 (77.4) |
| Less than four glands resected | 14 (22.6) |
| Weight of resected parathyroid tissue (g) | 2.56 ± 1.56 |
| Pathology of parathyroid tissue, no. of patients (%) | |
| Hyperplasia | 59 (95.2) |
| Adenoma | 3 (4.8) |
Abbreviations: PD Peritoneal dialysis, HD Hemodialysis, iPTH intact parathyroid hormone, ALP alkaline phosphatase
aAdjusted by serum albumin level